Navigation Links
Gene abnormality found to predict childhood leukemia relapse
Date:1/7/2009

Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL). Although the researchers caution that further research is needed to determine how changes in the gene, called IKZF1 or IKAROS, lead to leukemia relapse, the findings are likely to provide the basis for future diagnostic tests to assess the risk of treatment failure. By using a molecular test to identify this genetic marker in ALL patients, physicians should be better able to assign patients to appropriate therapies.

The findings of the Children's Oncology Group (COG) study, led by scientists from St. Jude Children's Research Hospital, Memphis, Tenn., the University of New Mexico Cancer Research and Treatment Center, Albuquerque, N.M., and the National Cancer Institute (NCI), part of the National Institutes of Health, appear online Jan.7, 2009, in the New England Journal of Medicine, and in print on Jan. 29, 2009.

ALL, a cancer of the white blood cells, is the most common childhood cancer, in that it affects about one in 29,000 children annually. Using currently available therapies, cure rates for ALL are now upwards of 80 percent. However, those therapies carry with them substantial side effects, and even with treatment, only 30 percent of children who experience a relapse of ALL will survive five years. Determining the risk of relapse faced by an individual patient would help physicians tailor treatment intensity appropriately, but until now there has been no good marker for predicting outcome.

"Great progress has been made in recent years in improving the cure rate of childhood ALL," said Stephen Hunger, M.D., chairman of the COG ALL committee and the lead COG investigator on this study. "The findings of this study help us further subdivide those patients who are unlikely to be cured, and identify patients in whom different therapies should be tested."

In the study, resear
'/>"/>

Contact: NCI Office of Media Relations
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Urologists report success using robot-assisted surgery for urinary abnormality
2. Study links primary insomnia to a neurochemical abnormality in young and middle-aged adults
3. One Species Genome Found Within Another
4. National Patient Safety Foundation Partners with Vocera Communications
5. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
8. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
9. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
10. The Tug McGraw Foundation Announces 2007 Fundraising Gala
11. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... XenaCare Holdings has anno... Arthritis Foundation, one of the largest nonprofi...d public health education. , ...XenaCare Holdings, Inc. (OTCBB: XCHO), a company s...on of consumer healthcare products, has announced ...
(Date:11/27/2009)... Multi-purpose bilingual co...esigned for use by the business community to educa...y of subjects from Safety issues to Dinosuars to A... Saint Louis, MO (PRWEB) November 27, 200...lectronics or toys to keep them busy any hour of t...
(Date:11/26/2009)...In the next 25 years, the number of Americans livi...om 23.7 million in 2009 to 44.1 million in 2034. O...ost triple, rising from $113 billion to $336 billi...sity, researchers based at the University of Chica.... , The number of those with diabetes covered by...
(Date:11/26/2009)... Dr. David Kim of the Live ...s surgery in Dallas , is one of a growing number o...social networking sites to connect with individual...ment to fight morbid obesity. Dr. Kim is utilizing...ormation about his practice with the community. ,...
(Date:11/25/2009)..., , KANSAS CITY, Mo., Nov. 25 /PRNewswire/ ...ily become the nation,s largest medical clinic on ...series of massive free clinics for uninsured peopl... to be the biggest one yet, because it will extend...weekdays instead of over a weekend," Sheri Wood, e...
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Kansas City Prepares for Largest Free Health Clinic 2
...add years to your life, Danish researchers find , ...inking in moderation and keeping physically active...Danish researchers report. , In fact, people who d...id both. , "This study is consistent with a numbe...
...gic Intelligence and Competitive Analysis Informat...(TM), PHILADELPHIA and LONDON, Jan. 9 Thomson,Sc...TOC ; TSX: TOC) and,leading provider of informatio...atters series analyzes the U.S. generics,market fr...
...ble New Daily Dosing Option for the Treatment of E...NYSE: LLY ) announced today that the U.S. Food an... (tadalafil)(1) for once daily use (2.5 mg and,5 m...tivity at anytime between doses., Currently avail...
... NBTY, Inc. (NYSE: NTY ), (http://www.NBTY.com ),...ritional,supplements, today announced preliminary ...uarter ended December 31, 2007., NBTY preliminary...nary and Unaudited) FOR THE FISCAL FI...
...ing Small Steps for Big Rewards, CINCINNATI, Jan.... Speaking of Women,s Health will be holding its Co...cross America on Saturday, January 12,from 11 a.m....s for their overall health and well-being., The b...
... Quality Assurance Certifies Quality of Health ...n. 8 AMERIGROUP Community Care of,Georgia announc...Accreditation by the National Committee for Qualit...ses and,reports on the quality of the nation,s man...
Other Medicine News:Health News:Drink a Little, Stay Active, Save Your Heart 2Health News:Drink a Little, Stay Active, Save Your Heart 3Health News:Thomson Scientific Introduces a New Quarterly Report Identifying the 'Movers and Shakers' in the U.S. Generics Industry 2Health News:Thomson Scientific Introduces a New Quarterly Report Identifying the 'Movers and Shakers' in the U.S. Generics Industry 3Health News:Thomson Scientific Introduces a New Quarterly Report Identifying the 'Movers and Shakers' in the U.S. Generics Industry 4Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 2Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 4Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 5Health News:NBTY Announces Fiscal First Quarter Preliminary Unaudited Net Sales Results 2Health News:NBTY Announces Fiscal First Quarter Preliminary Unaudited Net Sales Results 3Health News:Speaking of Women's Health 'Community Event' Returns to All Wal-Mart Supercenters Nationwide January 12th 2Health News:Speaking of Women's Health 'Community Event' Returns to All Wal-Mart Supercenters Nationwide January 12th 3Health News:AMERIGROUP Community Care of Georgia Wins New Health Plan Accreditation from NCQA 2
(Date:11/27/2009)...TON, Minn, Nov. 27 ACUO TECHNOLOGI...anagement software, data migration tools and servi... Patent and Trademark Office has approved a patent...thin a Computer Network." Acuo Technologies is ple...tellectual property. In general, the granted paten...
(Date:11/25/2009)...A PARK, Calif., Nov. 25 Praxis Ele...ngs in the American Academy of Family Physicians, ...ser Satisfaction Survey for improving medical qual...ll critical for new ARRA Stimulus legislation. Pra...EMR had a positive effect in determining their sal...
(Date:11/25/2009)...ORD, Mass., Nov. 25 Holo...), a leading developer, manufacturer and supplier ...d surgical products dedicated to serving the healt...of the Radiological Society of North America (RSNA...gh December 3, 2009 to highlight our new SecurView...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Drug Combo May Offer Best Relief for Nerve Pain 58527 1Drug Combo May Offer Best Relief for Nerve Pain 58527 2Australian study sheds light on kidney repair and disease 10181 1Australian study sheds light on kidney repair and disease 10181 2Cardinal Health Foundation Invites Health Care Providers to Apply for 241 Million in Grants to Improve Efficiency Quality of Care 58524 1Cardinal Health Foundation Invites Health Care Providers to Apply for 241 Million in Grants to Improve Efficiency Quality of Care 58524 2
...ee large PEGINTRON(TM) clinical studies address ke...OPENHAGEN, Denmark, April 27 Schering-Plough Corp...esults of three large PEGINTRON(TM) (peginterferon...estions in the hepatitis C research community and ...udies, involving a total of more than 2,700 patien...
...s $10 million milestone payment to Pharmasset , ,...aq: VRUS ) and Roche (Roche SWX: RO, ROG; Pink S...nt has been dosed in a Phase IIb study of R7128, t...n development for the treatment of chronic hepatit...uration of treatment of R7128 in combination with ...
Other Medicine Technology:Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 9Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 10Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 11Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10
ENDOlap™ 25 liter Heated Insufflator
Insufflators
KLEPPINGER bipolar forceps
...thologist to visualize the presence of Human Papil... choice of sample types: tissue, monolayer-based p...ocktails utilize proprietary probe formulations. T... genotypes 16, 18, 31, 33, 35, 39, 51, 52, 56, 58,...
Medicine Products: